Russian Federation: Changes To Federal Law 61-FZ On The Circulation Of Medicines And The RF Law On Veterinary Medicine

Last Updated: 20 July 2015
Article by Anna McDonald

Changes to Federal Law 61-FZ on the Circulation of Medicines

On July 13, 2015 a new set of amendments to Federal Law No. 61-FZ on the Circulation of Medicines of April 12, 2010 was approved by Federal Law No. 241-FZ on Amendments to the Federal Law on the Circulation of Medicines (hereinafter "Law 241-FZ"). The amendments have become the subject of criticism due to a number of provisions of Law 241-FZ.

Law 241-FZ clarifies in particular the set of documents required to confirm state registration of a pharmaceutical for medical application, whether such confirmation is requested before or after January 1, 2016. At the same time, the list of documents required for the respective application after January 1, 2016 includes a copy of a report on the pharmaceutical manufacturer's compliance with the good manufacturing practice rules (hereinafter the Rules) to be issued by the RF Ministry of Industry and Trade. Considering the number of manufacturers to be audited for such compliance, and also the novelty of this requirement and the absence of an approved procedure for carrying out such audits by the Ministry of Industry and Trade, it seems unlikely that the audit of all manufacturers will be successfully completed by the end of 2015. At the same time, foreign manufacturers of pharmaceuticals for veterinary use may submit a report on compliance with the Rules from a competent body of the manufacturer's country by 2017. Accordingly, unless the said deadline is postponed until a later date, the registration of pharmaceutical products for medicinal use by Russian manufacturers after January 1, 2016 may become impossible in practice and, therefore, no new pharmaceutical products will enter the market.

Further difficulties are created by the change in definition of the term "reference drug." That term introduced on July 1, 2015 means a drug that is registered for the first time, the quality, efficacy and safety of which have been proven on the basis of results of pre-clinical and clinical trials, and which is used to evaluate the bioequivalence or therapeutic equivalence, quality, efficacy and safety of a generic or analogue (biologically similar) drug. According to Law 241-FZ, a reference drug must go through the trials stipulated by Federal Law No. 429-FZ on Amendments to the Federal Law on the Circulation of Medicines of December 22, 2014 (hereinafter "Law 429-FZ"), including those of its provisions which are entering into force in 2016. This formally makes it impossible to register a drug as a reference drug before 2016. To prevent a collision between the above-mentioned provisions of law, Law 241-FZ clarifies that until January 1, 2016 an original drug shall be considered as the reference drug. It is worth noting that the very term "original drug" (apparently intended for applying Law 241-FZ) has already been removed from the legislation. According to comments from the Director of the Department of Drug Supply and Regulation of the Circulation of Medical Devices of the Russian Ministry of Health Yelena Maksimkina1, although the term was removed from the law, original drugs that have already been registered will retain their status and will be used as reference drugs. One can only hope that the Russian Health Ministry will indeed follow this principle in practice when registering pharmaceuticals.

At the same time, Law 241-FZ emphasizes the status of reference drugs for veterinary use, clarifying that such drugs must go through pre-clinical and clinical trials in accordance with the requirements established for veterinary drugs. In general, a number of provisions of law are made more detailed by Law 241-FZ, specifically regarding pharmaceuticals for veterinary use. For example, the list of documents to be sent together with the terms of reference for expert review of a veterinary pharmaceutical has been clarified, a procedure for completing the application for confirmation of state registration of a veterinary drug and the documents attached to the application has been detailed.

In addition to this, Law 241-FZ clarifies a number of provisions regarding the powers and interaction of government agencies, including for setting prices on so-called essential (vital) drugs. In order to get expedited expert review of drugs the order of applications for state registration is defined as under one international nonproprietary name of the drug or drug grouping name.

Law 241-FZ also indicates the sequence of actions to be taken when violations of the rules are discovered during the clinical trial of a drug. If such violations affect the completeness and accuracy of the clinical trial, then the competent body (the Federal Healthcare Supervisory Service) suspends the trial and issues an order to remedy the violations. If the medical organization conducting the trial fails to remedy the violations within the stated time period, a decision is taken to stop that trial.

It is also clarified that state registration of drugs for which applications are filed before the effective date of Law 429-FZ, and review of applications for state expert review of drugs filed before the effective date of Law 429-FZ follow the rules of law in effect prior to the entry into force of Law 429-FZ.

Changes to the Russian Federation Law on Veterinary Medicine

On July 1, 2015 the State Duma adopted in the third reading, and on July 8 the Federation Council approved the Federal Law on Amendments to the Russian Federation Law on Veterinary Medicine and Certain Legislative Acts of the Russian Federation. That Federal Law introduces significant changes to the legislation on veterinary medicine.

In particular, it is planned that the Russian Federation Ministry of Agriculture will adopt veterinary regulations governing all areas of veterinary medicine and various types of veterinary activity.

Also, it is intended to create the Federal State Veterinary Information System in which veterinary documents accompanying the products will be generated electronically (which will be mandatory starting January 1, 2018). The Law sets out the principle that veterinary supporting documents will be generated free of charge and that the competent governmental body has the duty to issue them in hard copy at the request of the owner of the product covered by the veterinary control requirement.

The Law obliges the RF Government to develop and approve a procedure for creating, developing and operating the Federal State Veterinary Information System, although it does not set the deadline for such procedure to be put in place. It is also provided that such procedure shall contain requirements to ensure access of individuals and legal entities to information contained in the Federal State Veterinary Information System, to enter information in the system, to obtain information from the system and register those entities in the system.

The Federal State Veterinary Information System will contain, in particular, information about pharmaceuticals, feeds and feed supplements for animals. Inasmuch as the Law does not provide for any provisions governing the procedure for entering data on pharmaceuticals, feeds and feed supplements for animals that have already been registered in that Federal System, it would be reasonable to suppose that such provisions will be included in the procedure for creating, developing and operating the said Federal Veterinary Information System, which the RF Government is responsible for developing and approving, as mentioned above.



The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.